Iconic Therapeutics (Atlanta, GA) is developing hI-con1™, a fusion protein therapeutic invented at Yale by Drs. Alan Garen and Zhiwei Hu. While hI-con1 may have utility against cancer (solid tumors) and other diseases, development has been focused on its utility in treating the wet form of age-related macular degeneration (“wet AMD”), the leading cause of blindness in the elderly. Elm Street Ventures partner Mike Sherman (now retired) was a co-founder of the company, which raised its first capital in 2003, and served as the CEO and Chairman. Iconic raised a substantial financing round in late 2015 that will carry the company through additional clinical trials.